Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Annie Duffy

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
HIV Medicine|December 1, 2023
HIV pre-exposure prophylaxis services, provision, and delivery in the European treatment network of HIV, hepatitis and global emerging infectious diseases (NEAT ID)Geoffroy Liegeon, Annie Duffy, Caroline Brooks, et al.
Emergency Medicine Journal : EMJ|November 6, 2014
The Mersey Burns App: evolving a model of validationJamie Barnes, Annie Duffy, Nathan Hamnett, et al.
The Lancet. HIV|February 28, 2024
Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trialGraeme Moyle, Lambert Assoumou, Nathalie de Castro, et al.
Infectious Diseases Now|July 16, 2023
Clinical outcomes by supplemental oxygen use in remdesivir-treated, hospitalised adults with COVID-19Nadir Arber, Pallav L Shah, Lambert Assoumou, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
HIV Medicine|December 1, 2023
HIV pre-exposure prophylaxis services, provision, and delivery in the European treatment network of HIV, hepatitis and global emerging infectious diseases (NEAT ID)Geoffroy Liegeon, Annie Duffy, Caroline Brooks, et al.
Emergency Medicine Journal : EMJ|November 6, 2014
The Mersey Burns App: evolving a model of validationJamie Barnes, Annie Duffy, Nathan Hamnett, et al.
The Lancet. HIV|February 28, 2024
Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trialGraeme Moyle, Lambert Assoumou, Nathalie de Castro, et al.
Infectious Diseases Now|July 16, 2023
Clinical outcomes by supplemental oxygen use in remdesivir-treated, hospitalised adults with COVID-19Nadir Arber, Pallav L Shah, Lambert Assoumou, et al.
Pageof 1